GlassScriptPhysician profile
Morgan Keeter
NPI 1528691300
$441.20
in general payments reported to CMS, 2019-2025
11 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.38 · 2023: $123 · 2024: $173 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $67.23 | 2023 | Farxiga |
| Ironshore Pharmaceuticals INC. | $66.71 | 2023-2024 | Jornay Pm |
| Pfizer INC. | $57.76 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $47.36 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $44.43 | 2024-2025 | Vaxneuvance, Proquad, Rotateq |
| Corium, LLC | $38.31 | 2024 | Azstarys |
| Aytu Biopharma, INC. | $35.63 | 2022-2023 | Karbinal |
| Supernus Pharmaceuticals, INC. | $31.19 | 2024 | Qelbree |
| Phadia US INC. | $24.31 | 2025 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $15.21 | 2025 | Zoryve |
| Organon LLC | $13.06 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Keeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.